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22 studies with a total of 254,894 participants of European ancestries and age 60 or older were 
included in the analysis low grip strength. See Supplementary Table 1 for number of cases/controls 
in each cohort. Here follows individual study descriptions: 
 
Atherosclerosis Risk in Communities (ARIC) study 
The Atherosclerosis Risk in Communities (ARIC) Study is a population-based prospective cohort study 
of cardiovascular disease and includes a total of 15,792 participants aged 45-64 years at baseline 
(1987-89), chosen by probability sampling from four US communities(1). Cohort members 
completed five clinic examinations, conducted approximately three years apart between 1987 and 
1998, with a fifth visit conducted from 2011 – 2013. Clinic examinations included assessment of 
cardiovascular risk factors, self-reported medical family history, employment and educational status, 
diet, physical activity, comorbidity, clinical and laboratory measurements. The present analyses were 
restricted to participants of European descent and utilized measurements from the Visit 5 grip 
strength assessment. Grip strength in kilograms of force was assessed using Jamar Hydraulic Hand 
Dynamometer in the participant's preferred hand (usually the dominant). The better of two trials 
was used for the dynapenia definitions and subsequent association analyses.  
Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, 
Santa Clara, CA, USA). Exclusions at the individual level included removing first-degree relatives, 
ancestry outliers, samples with low call rate (<95%) or unexpected duplicates, and samples with a 
mismatch between called and phenotypic sex. SNPs were excluded due to having a low call rate for 
the combined sample (<95%), no chromosome location, being monomorphic in both the European 
and African descended genotyped individuals, and having an HWE p-value <10-6. Before imputation, 
additional quality control was completed using the “HRC/1KG Imputation Preparation and Checking 
Tool” developed by Will Rayner (version 4.2.5). SNPs with incorrect strand or reference/alternate 
allele designations were fixed accordingly and further SNPs were excluded due to mismatches with 
the 1000 Genomes reference panel, having allele frequency differences >0.2 from the European 
1000 Genomes data, and being palindromic with frequencies >0.4. A total of 752,325 SNPs were 
submitted for imputation on the Michigan Imputation Server using the Haplotype Reference 
Consortium (HRC) r1.1 2016 reference panel with the following options chosen: phasing, Eagle v2.3; 
population, EUR (for quality control purposes); mode, Quality Control & Imputation. 
After filtering for age, phenotype, genotype availability and removing all related individuals, 3655 
individuals remained, with a minimum age of 66 and a maximum of 90. The number of cases and 
controls for each analysis/dynapenia definition is as follows: for FNIH, 351 cases and 3,304 controls; 
for EWGSOP, 939 cases and 2,716 controls. Logistic regression analyses were conducted using the ‘--
logistic-snp’ option on FAST (version 2.4)(2) with imputed continuous dosage data. Covariates for 
adjustment included age, sex (except in the sex-stratified analyses), study site and PCs 1-4. Only 




Berlin Aging Study II (BASE-II) 
BASE-II is a multidisciplinary study initiated in 2009 investigating factors related to human aging (3). 
All subjects are recruited from the Berlin metropolitan area and underwent an extensive phenotypic 
assessment, including a 2-day internal medicine examination (follow-up will be completed in 2020). 
The BASE-II research project (Co-PIs are Lars Bertram, Ilja Demuth, Denis Gerstorf, Ulman 
Lindenberger, Graham Pawelec, Elisabeth Steinhagen-Thiessen, and Gert G. Wagner) is supported by 
the German Federal Ministry of Education and Research (Bundesministerium für Bildung und 
Forschung, BMBF) under grant numbers #16SV5536K, #16SV5537, #16SV5538, #16SV5837, 
#01UW0808, 01GL1716A and 01GL1716B. Another source of funding is the Max Planck Institute for 
Human Development, Berlin, Germany. Additional contributions (e.g., equipment, logistics, 
personnel) are made from each of the other participating sites. 
Genome-wide SNP genotyping was performed using the "Genome-Wide Human SNP Array 6.0" 
[Affymetrix, Inc]) on the full BASE-II dataset (3). For full QC and imputation procedures see (REF: 
PMID 26821332). Briefly, genome-wide imputation of unobserved genotypes was carried out on the 
QC’ed data using IMPUTE2 v2.2.2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) based 
on precompiled ‘ALL 1000G Phase1 integrated haplotypes' reference panels (December 2013 
release) [14]. A total of 27,213,648 SNPs were imputed, but only autosomal SNPs with an IMPUTE 
info value ≥0.35 and minor allele frequencies ≥1% were retained for subsequent analyses. Overall, 
genotype and hand grip strength data were available in 1,531 unrelated (i.e. IBD/IBS sharing >12.5% 
using –genome in PLINK1.9) BASE-II participants aged 60+. To calculate PCs to be used as co-variates 
in the genome-wide analyses, LD pruning was applied to pre-imputation genotype data using PLINK 
(--indep-pairwise 1500 150 0.2) resulting in 117835 SNPs. Eigenvalues and eigenvectors were then 
calculated using PLINK (–pca). Based on the resulting scree plot, we selected the first 10 PCs as 
covariates. For the actual GWAS we used SNPTEST 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) v2.5.4-beta3 ( -frequentist 
1 -method score -cov_names PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 age -cov_names sex (for 
combined phenotypes only)). 
 
B-Vitamins for the PRevention Of Osteoporotic Fractures (BPROOF) study 
The B-PROOF study is a randomized, placebo-controlled, double-blind trial that studied the effect of 
vitamin B12 and folic acid supplementation on osteoporotic fractures in 2,919 people of 65 years or 
over, and having homocysteine levels of 12-50 µmol/L. Participants were recruited between 2008 
and 2011 and followed during a 2-3 year period (4). Genotyping was done by using the Illumina 
Omni-express array. Imputations to HRC1.1 were performed using the Michigan Imputation Server 
with standard settings. The GWAS analyses were performed using rvtest. 
 
Cardiovascular Health Study (CHS) 
The Cardiovascular Health Study is a population-based, prospective cohort study of risk factors for 
development and progression of CHD and stroke in older adults ages 65 years or older (5). A cohort 
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of 5,201 non-institutionalized men and women were selected and enrolled from randomly 
generated Medicare eligibility lists in 4 U.S. communities in 1989-90; an additional 687 
predominantly African American participants were recruited and enrolled in 1992-93. Clinic 
examinations were performed at study baseline, at annual visits through 1999, and again in 2005-
2006. Participants were contact by telephone annually between exams, and every 6 months after 
the exams ended. Multiple physical and biological tests have been performed, including assessment 
of physical function. The current analysis included 3,061 CHS participants of European ancestry for 
whom genotype and grip strength data were available. 
Blood samples were drawn from all participants at their baseline examination and DNA was 
subsequently extracted from available samples. Genotyping was performed at the General Clinical 
Research Center’s Phenotyping/Genotyping Laboratory at Cedars-Sinai among CHS participants who 
consented to genetic testing and had DNA available using the Illumina 370CNV BeadChip system. 
CHS was approved by institutional review committees at each field center and individuals in the 
present analysis had available DNA and gave informed consent including consent to use of genetic 
information. 
Imputation to the HRC r1.1 2016 panel was performed on the Michigan imputation server. SNPs 
were excluded for variance on the allele dosage ≤0.01. The GWAS was conducted using a custom 
program written in R. Logistic regression models adjusted for age, sex (for the combined analyses), 
field center, and principal components were fit. 
 
European Prospective Investigation of Cancer (EPIC) Norfolk  
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study 
(https://dx.doi.org/10.22025/2019.10.105.00004) is a prospective population-based cohort study 
which recruited 25,639 men and women aged 40-79 years at baseline between 1993 and 1998 from 
35 participating general practices in Norfolk, UK. Individuals attended for a baseline health check 
including the provision of blood samples for concurrent and future analysis. Further health check 
visits have been conducted since the baseline visit.  Participants have contributed information about 
their diet, lifestyle and health through questionnaires and health checks over two decades. The 
Norwich Local Research Ethics Committee granted ethical approval for the study. All participants 
gave written informed consent.  Grip strength measurement was taken at the third (2004-2006), the 
fourth (2012-2016) and the fifth (2016-2018) health checks. To maximum the sample size, we take 
grip and related measures from a late health check visit if it is unavailable at previous visit. Related 
samples, ethnic outliers and participants whose age was less than 60 years old were excluded from 
further analysis. 
DNA has been extracted from all EPIC participants and stored blood has been analysed for an 
extensive range of classical and novel biomarkers. Samples were genotyped using Affymetrix Axiom 
array at Cambridge Genomic Services, Department of Pathology, University of Cambridge, UK, and 
samples were excluded if lower call rate (<95%), or heterozygosity outliers, or gender mismatch, or 
failed channel contrast (DishQC <0.82), or unusually high number of singleton genotypes, or 
impossible IBD values.  SNPs were removed if lower call rate (<95%), or MAF=0, or failed HWE (p<10-
6), or clusters failed Affymetrix SNPolisher standard tests and thresholds, or MAF significantly 
affected by plate, or duplicates or unflippable.  A total of 21044 samples were forwarded to 
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imputation using HRC r1 reference panel, and using UK10K+1000Gp3 reference panel for additional 
SNPs.  
GWAS analysis was performed on 7508 participants using SNPTEST v2.5.4-beta3 (-method newml) 
under an additive model with covariates age, sex, and the first 10 principal components.   
 
Framingham Heart Study 
The Framingham Heart Study (FHS) is a single-site, community-based cohort study that was initiated 
in 1948 to investigate risk factors for cardiovascular disease and other major illnesses. The FHS 
includes three generations: the original cohort followed since 1948 (Gen1) (6); their offspring and 
spouses of the offspring, followed since 1971 (Offspring or Gen2) (7); and children of the offspring  
enrolled in 2002 (Third Generation or Gen3) (8). The Original cohort enrolled 5,209 men and women 
who comprised two-thirds of the adult population then residing in Framingham, MA, USA. The 
Offspring cohort comprises 5,124 persons who have been examined about every 4 to 8 years. 
Examination 1 of the Gen3 occurred between 2002 and 2005 and involved 4,095 participants. 
Offspring spouses not previously enrolled who were a biological parent of a Gen 3 participant were 
enrolled into the New Offspring Spouse cohort to complete family pedigrees. All cohorts continue 
under active surveillance. The FHS follows two multi-ethnic cohorts, Omni group 1 and Omni group 2 
to reflect the current diversity of the town of Framingham, MA.  
In the 1990s and early 2000s, DNA samples were collected in the Original, Offspring, Third 
Generation, and Offspring Spouse cohorts of the FHS. All individuals provided consent for 
genotyping. NHLBI funded genotyping using 550,000 SNPs (Affymetrix 500K mapping array plus 
Affymetrix 50K supplemental array). Imputations were performed with miniMACH3 using the HRC 
release 1.1 reference panel for SNPs passing the following criteria: call rate ≥ 97%, pHWE ≥ 10-6, < 
100 Mendel errors, and MAF ≥ 1%.  
Grip strength was recorded by trained technicians at the time of Offspring exam 7, exam 8 and exam 
9 and Gen 3 exam 2, using a Jamar dynamometer. The maximum of six trials (three trial in each 
hand) was used. For participants with hand grip data at more than one examination, the first exam 
the individual was age 60 or older was used for analysis. The Boston University Medical Campus IRB 
approved the content of all examinations and participant provided informed consent at all attended 
exam. 
 
Health and Retirement Study (HRS) 
The Health Retirement Study is representative American cohort with participants over age 50 to 
monitor factors related to aging and retirement (9,10). A random subset of ~26,000 participants 
were selected in three phases (phase 1 in 2006, phase 2 in 2008, and phase 3 in 2010) to collect 
biological specimen between 2006 and 2010. The DNA samples were genotyped at the Center for 
Inherited Disease Research (CIDR) on Illumina HumanOmni2.5 array, Phases 1-2 on HumanOmni2.5-
4v1 and Phase 3 on HumanOmni2.5-8v1. Both arrays are designed to human genome build 37. 
Imputation analyses were performed using IMPUTE version 2.3 (11).  
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Genotyping data were available for 15,708 samples (6519 males and 9189 females) in the combined 
Phase 1-3 dataset.  15,454 remained after filtering related or duplicated samples, genotyping 
controls, and those with a missing call rate ≥ 2%. 12,940 (84%) were Whites. Of which, 10,919 
reached 60 years old. The grip strength was measured using a medley spring-type hand 
dynamometer. Two measurements were taken from each hand and the maximum at the most 
recent visit was used to conduct association analyses. Grip strength ≥ 90 kg was considered unreal 
and set to missing based on actual data distribution. Dynapenia was determined based on the 
EWGSOP or FNIH definition. 10,814 white participant (4650 males and 6164 females) had both 
genotyping and grip strength data. 3624 (34%) and 1754 (16%) met the EWGSOP and FNIH criteria, 
respectively. Women were more likely to have dynapenia than men by the EWGSOP (39% vs. 27%) 
or FNIH (18% vs. 14%). 
In genome-wide association analyses, the EWGSOP or FNIH dynapenia was associated with SNPs, 
one at a time, in a linear mixed effects model, including additive allelic effect of the candidate SNP, 
sex (if not sex-specific), age at measurement, plus random polygenic and environment effects. The 
analyses were conducted using the BOLT-LMM version 2.2 (12), with precomputed LD scores from 
Europeans in the 1000 Genomes.  
 
InCHIANTI study 
The InCHIANTI study is a population-based epidemiological study aimed at evaluating the factors 
that influence mobility in the older population living in the Chianti region in Tuscany, Italy. The 
details of the study have been previously reported (13). Briefly, 1616 residents were selected from 
the population registry of Greve in Chianti (a rural area: 11,709 residents with 19.3% of the 
population greater than 65 years of age), and Bagno a Ripoli (Antella village near Florence; 4,704 
inhabitants, with 20.3% greater than 65 years of age). The participation rate was 90% (n=1453), and 
the subjects ranged between 21-102 years of age. Overnight fasted blood samples were for genomic 
DNA extraction. Maximal isometric hand grip strength was measured in kilograms using a hand-held 
dynamometer (Smith & Nephew, Agrate Brianza, Milan, Italy). The subject was seated in front of a 
bench with the tested arm supported on the bench and the elbow flexed to 45°. Participants were 
asked to perform the task twice with each hand, and the maximum strength attained during the four 
trials was used for the present analyses. Dynapenia was determined using the FNIH criteria and 
EWGSOP criteria. The study protocol was approved by the Italian National Institute of Research and 
Care of Aging Institutional Review and Internal Review Board of the National Institute for 
Environmental Health Sciences (NIEHS). All participants provided written informed consent. 
Genome-wide genotyping was conducted using Illumina Infinium HumanHap 550K SNP arrays (14). 
Genotyping was completed for 1210 subjects with a sample call rate >97%, heterozygosity rates > 
0.3 and correct sex specification. 495,343 autosomal SNPs that passed quality control (MAF>1%, 
completeness >99%, HWE > 10-4) were used for imputation using as reference the Haplotype 
Reference Consortium (HRC) panel, version 1.1. The imputation was done using Minimac, and the 
process was facilitated by the Michigan Imputation server (15). Associations between grip strength 
and SNP dosages was performed using logistic regression in PLINK 1.9, adjusting for age, sex (except 
sex-specific analyses), study site, and 10 principal components. 
 
LASA:  Longitudinal Aging Study Amsterdam 
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Longitudinal Aging Study Amsterdam (LASA) is an ongoing, population-based cohort of individuals 55 
years and older living in the Netherlands. The design and rationale is described elsewhere (16,17). In 
short, 3017 participants (55-84 years old) were included at baseline (1992-1993) and two additional 
cohorts were added in 2002-2003 and 2012-2013 with respectively 1002 and 1023 participants. 
Follow-up visits were conducted every 3 years. Trained interviewers collected data on cognitive, 
emotional, physical and social functioning during a home interview. Subsequently, all participants 
were invited for a medical interview during which further diagnostic examinations were done and 
blood samples were drawn. LASA has been approved by the Medical Ethics Committee of VU 
University Medical Center. All participants gave written informed consent. 
DNA was isolated from buffy coats or full blood samples drawn at baseline. Genotyping was done 
using two arrays: Axiom-NL Array (Affymetrix Inc, Santa Clara, CA., USA) and Infinium Global 
Screening Array (GSA) (Illumina Inc, San Diego, CA., USA). Quality control (QC) was done separately 
for each array using Ricopili (Rapid Imputation for COnsortias PIpeLIne for GWAS), an established 
tool developed by the Psychiatric Genomics Consortium (18). After QC, the data was imputed using 
as reference the Haplotype Reference Consortium (HRC) panel, version 1.1 (19). The imputation was 
done using Minimac 3, and the process was facilitated by the Michigan Imputation server(20). 
Grip strength was measured during the medical interview using a dynamometer (Takei TKK 5001, 
Takei Scientific Instruments Co. Ltd., Tokyo, Japan) and it was recorded in the nearest 1 kg. 
Dynapenia was determined using the FNIH criteria and EWGSOP criteria. 
The analyses were performed separately per genotyping array and were adjusted for age, sex 
(except sex-specific analyses), 10 principal components and cohort (for the GSA array). Logistic 
regression in Plink v.1.9 was used. 
 
Long-Life Family Study 
The Long Life Family Study is a multi- centre international study on the genetics and familial 
components of exceptional survival. Between 2006 to 2009, LLFS successfully enrolled and rigorously 
phenotyped probands, their siblings, and children of families demonstrating exceptional survival 
(4,953 individuals from 539 families; N=1727 probands; 3226 offspring). LLFS includes: Field centres 
at Boston University, Columbia University, University of Pittsburgh, and University of Southern 
Denmark, at Laboratory Core (University of Minnesota) and a Coordinating Center (Washington 
University in St. Louis). In brief, the LLFS recruited selected families with multiple exceptionally old 
living individuals, the probands were ≥79 years old in the USA, and ≥90 years old in Denmark. 
Families were selected to participate in the study based on The Family Longevity Selection Score 
(FLoSS) (21) which calculated the rank sibships by current age or age at death of siblings, the size of 
the sibship and the number of alive individuals available for study. A proband's family was eligible if 
the FLoSS reached a score of 7 or higher, which met the following criteria: (1) the proband, at least 
one living sibling, and one of their living offspring (minimum family size of 3) were all able to give 
informed consent, and (2) were willing to participate in the interview and examination including the 
blood sample for serum and DNA extraction. The age of the 3359 participants who were aged 60 




Grip strength was measured using a JAMAR® hand-held dynamometer (Sammos Preston Rolyan, 
Bolingbrook, IL). Two trials for each were conducted, and the maximum value for the strongest hand 
was used in analyses. 
Genotype data were produced on 4,716 of the consented LLFS subjects using the Illumina 2.5 million 
HumanOmni array, with the purpose of utilizing them in genome-wide association (GWA) analyses. 
Genotypes were called using Bead Studio. LLFS QC of the genotypes included using the package GRR 
(Graphical Representation of Relationships)(22) to check familial relationships and sample switches 
based on Identity-by-State genotypes. Corrections to familial relationships were made as warranted 
by the data.  After GRR, additional QC included removing 18 samples with autosomal call rates less 
than 97.5%, leaving 4,693 (4,597 with EU ancestry) subjects for further analysis.  To determine and 
exclude outliers with respect to ancestral population, we generated principle components (PCs) with 
smartpca2016 (23) from 112,639 Tag SNPs in 4,597 (of 4,693) LLFS samples of European Ancestry 
and included 2,504 haplotypes from 1000 genomes Cosmopolitan panel to support ancestral 
clustering.  18 additional individuals of the 4,597 samples with EU ancestry were identified as PCs 
outliers and removed prior to imputation.  Further, we calculated sample heterozygosity and 
removed 5 outliers (3 overlap in PCA outliers) with excess heterozygosity, i.e. heterozygosity > 
median + 3*IQR, thereby leaving 4,577 samples for imputation.   
SNP QC included using Loki (24) to identify all Mendel errors in SNPs among families. 3,647 SNPs 
were identified as outliers with respect to total number of detected Mendelian errors and were 
excluded. All other genotype calls resulting in Mendel errors were set to missing, which occurred 
153,363 times in our data. SNPs with a call rate lower than 98% were also excluded (n=83,774; 1,188 
of these were also Mendelian outlier SNPs). Applying both the call rate and Mendelian error criteria, 
86,233 autosomal SNPs were removed, leaving 2,225,478 SNPs in the cleaned genotyped data 
passing QC criteria. 
From the SNPs that passed LLFS QC procedures, we applied the following criteria, per the MI server, 
to ensure the highest quality imputation. The imputation ‘scaffold’ for the MI server included SNPs 
from our cleaned genotyped SNPs (n=2,225,478) which met the following additional criteria: 1) 
Hardy-Weinberg equilibrium (p>=1E-06); 2) No allele mismatch when compared with 1000HG; 3) No 
position mismatch when compared with 1000HG (e.g. assembly GRCh37); 4) No association with 
known inversions between GRCh37 and GRCh38 (identified by order reversal between rs-named 
SNPs in b138 and b144 from NCBI annotation downloads); and 5) Monomorphic markers. 
The cleaned binary files (one for each chromosome) were then uploaded to the imputation server 
for pre-phasing and imputation in VCF format (after bgzip and tabix in the UNIX environment).  The 
final number of clean autosomal SNPs used for imputation was 1,559,272. Autosomal Imputation 
was performed on the Michigan Imputation Server (https://imputationserver.sph.umich.edu) by 
chromosome (e.g. 22 simultaneous jobs).  The reference panel used was HRC r1.1 2016, phasing was 
performed with Eagle v2.3, population was set to EUR., and the mode option employed quality 
control and imputation. 
GWAS was done using R package GENESIS via Bioconductor. The protocol in GENESIS is to first fit a 
null model without genotype data, which adjusts the outcome based on the covariates, principal 
components, and family correlations (GENESIS function ‘fitNullModel’). Genetic relatedness matrix is 
established using sample of independent genotyped SNPs, then specified as the covariance matrix in 
the mixed model. Population stratification is adjusted for by a set of principal components specific to 
the outcome, which are derived from the same sample of independent SNPs. This data is then used 
in SNP association tests (GENESIS function ‘assocTestSingle’), so that the mixed models only need to 
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be run once. Tests were adjusted for Age, sex (if combined sex analysis), field centre, principal 
components (for population stratification). Betas, SEs, and Odds ratios were separately calculated 












(3) 𝑂𝑅 = exp(𝐵𝑒𝑡𝑎) 
 
MrOS (Osteoporotic Fractures in Men) study 
The Osteoporotic Fractures in Men (MrOS) study is a multicenter, prospective study including older 
men in Sweden, Hong Kong and the United States. The MrOS Sweden study (n=3014) consists of 
three sub-cohorts from three different Swedish cities (n=1005 in Malmö, n=1010 in Gothenburg, and 
n=999 in Uppsala) (25). Study subjects (men aged 69 to 81 years) were randomly identified using 
national population registers.  A total of 45% of the subjects who were contacted participated in the 
study. To be eligible for the study, the subjects had to be able to walk without assistance, provide 
self-reported data, and sign an informed consent. The study was approved by the ethics committees 
at the Universities of Gothenburg, Lund, and Uppsala. Informed consent was obtained from all study 
participants. In this study 941 unrelated participants from Gothenburg and 891 unrelated 
participants from Malmö were included. 
A Jamar® hydraulic hand dynamometer (5030J1, Jackson, MI, USA), with adjustable handgrip, was 
used in the grip strength test. Participants were made to sit in a standard chair with the arm resting 
on a moveable table with the dynamometer in an upright position. Two trials were performed on 
each hand. The better of the two results (presented as kilograms of force) was used in the analyses. 
Grip strength was not measured if the subject had current arthritis or pain in the wrist or hand or 
had undergone fusion, arthroplasty, tendon repair, synovectomy or related surgery of the upper 
extremity in the 3 months preceding the test. The coefficient of variation was 0.5%. 
Genotyping, imputation and quality controls of MrOS Gothenburg were performed using the 
Illumina HumanOmni1_Quad_v1-0 B array. Genotypes were called using the Illumina’s BeadStudio 
calling algorithm. The sample quality control exclusion criteria were sample call rate < 97%, 
excessive autosomal heterozygozity, first and second degree relatives, genotypic sex mismatch using 
X and Y chromosome probe intensities and gross chromosome abnormalities. Genotyped SNPs with 
GenTrain scores <0.6, cluster separation scores <0.4, call rates <97%, or MAF <0.01 were excluded. 
Also, autosomal SNPs with Hardy-Weinberg Equilibrium P-value <10-4 were excluded and genotype 
clusters for SNPs on chrX, chrY, chrXY and chrMT were reviewed manually. 714543 autosomal SNPs 
passed quality control.  
Genotyping, imputation and quality controls of MrOS Malmö were performed using the 
HumanOmniExpress-12v1_B build 36. The sample quality control exclusion criteria were sample call 
rate < 97.5%, missing data, excessive autosomal heterozygozity, familiar relationship (one sample 
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excluded), genotypic sex mismatch, non-caucasians and gross chromosome abnormalities. SNPs with 
call rates<95% were excluded. 725409 autosomal SNPs passed quality control. 
The genotype data for both MrOS Gothenburg and MrOS Malmö were pre-phased first without a 
reference panel, using SHAPEIT2. The imputation was done using Sanger Imputation Service to the 
Haplotype Reference Consortium release 1.1. 
Associations between grip strength and SNP dosages were obtained using logistic regression in PLINK 
1.9, adjusting for age. 
 
ROSMAP: the Religious Orders Study (ROS) and Memory and Aging Project (MAP) 
The ROS, started in 1994, enrolled Catholic priests, nuns, and brothers, from about 40 groups in 12 
states (26). The follow-up rate of survivors exceeds 90%. Participants were free of known dementia 
at enrollment, agreed to annual clinical evaluations, and signed both an informed consent and an 
Anatomic Gift Act form donating their brains at time of death. Participants take a neuropsychological 
test battery. DNA was extracted from whole blood, lymphocytes, or frozen post-mortem brain 
tissue. Genotyping was performed at the Broad Institute’s Center for Genotyping and the 
Translational Genomics Research Institute and the Children's Hospital of Philadelphia.  
The Rush Memory and Aging Project, started in 1997, enrolled older men and women from assisted 
living facilities in the Chicago area with no evidence on dementia at baseline (26). The follow-up rate 
of survivors exceeds 90%. Participants agreed to annual clinical evaluations, and signed both an 
informed consent and an Anatomic Gift Act form donating their brains at time of death. Participants 
were invited to take a neuropsychological test battery. DNA was extracted from whole blood, 
lymphocytes, or frozen postmortem brain tissue. Genotyping was performed at the Broad Institute’s 




The Rotterdam Study is an ongoing prospective population-based cohort that investigates occurrence, 
determinants, and consequences of diseases in an ageing population (27). The first baseline 
measurement of Rotterdam Study started in 1990. After two expansions in 2000 and 2006, it 
comprised 14,926 participants aged 45 years and over by the end of 2008. Follow-up visits were held 
every 3-5 years. The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and 
Sport. All participants provided written informed consent to participate in the study and to have their 
information obtained from treating physicians. Imputations to HRC1.1 were performed using the 
Michigan Imputation Server with standard settings (15,19).  
 
Study of Health in Pomerania (SHIP) 
The Study of Health in Pomerania (SHIP) is a population-based project in West Pomerania, the north-
east area of Germany (28). A sample from the population aged 20 to 79 years was drawn from 
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population registries. First, the three cities of the region (with 17,076 to 65,977 inhabitants) and the 
12 towns (with 1,516 to 3,044 inhabitants) were selected, and then 17 out of 97 smaller towns (with 
less than 1,500 inhabitants), were drawn at random. Second, from each of the selected 
communities, subjects were drawn at random, proportional to the population size of each 
community and stratified by age and gender. Only individuals with German citizenship and main 
residency in the study area were included. Finally, 7,008 subjects were sampled, with 292 persons of 
each gender in each of the twelve five-year age strata. In order to minimize drop-outs by migration 
or death, subjects were selected in two waves. The net sample (without migrated or deceased 
persons) comprised 6,267 eligible subjects. Selected persons received a maximum of three written 
invitations. In case of non-response, letters were followed by a phone call or by home visits if 
contact by phone was not possible. The SHIP population finally comprised 4,308 participants 
(corresponding to a final response of 68.8%). The medical ethics committee of the University of 
Greifswald approved the study protocol, and oral and written informed consents were obtained 
from each of the study participants. Handgrip strength was assessed in the second five-year follow-
up of the study (SHIP-2) and used for this project. 
Nonfasting blood samples were drawn from the cubital vein in the supine position. The samples 
were taken between 07:00 AM and 04:00 PM, and serum aliquots were prepared for immediate 
analysis and for storage at -80 °C in the Integrated Research Biobank (Liconic, Liechtenstein). The 
SHIP samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. 
Hybridisation of genomic DNA was done in accordance with the manufacturer’s standard 
recommendations. Genetic data were stored using the database Caché (InterSystems). Genotypes 
were determined using the Birdseed2 clustering algorithm. For quality control purposes, several 
control samples where added. On the chip level, only subjects with a genotyping rate on QC 
probesets (QC callrate) of at least 86% were included. Finally, all arrays had a sample callrate > 92%. 
The overall genotyping efficiency of the GWA was 98.55 %. Imputation of genotypes was performed 
using the HRCv1.1 reference panel and the Eagle and minimac3 software implemented in the 
Michigan Imputation Server for pre-phasing and imputation, respectively. SNPs with a Hardy-
Weinberg-Equilibrium p-value <0.0001, a call rate <0.95, and monomorphic SNPs were removed 
before imputation. The GWAS were performed sex-stratified using EPACTS-3.2.6-patched adjusting 
for age, the (two) handgrip measurement devices, and the first 10 genetic principal components. 
 
Toledo Study for Healthy Aging (TSHA) 
Data were taken from the Toledo Study for Healthy Aging, a population-based study conducted on 
2,488 individuals aged 65 years and older. Study participants were selected by a two-stage random 
sampling from the municipal census of Toledo, covering both institutionalized and community 
dwelling persons from rural and urban settings. Data were collected from 2006 to 2009, and 
included information on social support, activities of daily living, comorbidity, physical activity, quality 
of life, depressive symptoms, and cognitive function. In addition, a nurse collected anthropometric 
data, conducted tests of physical performance (walk speed, upper and lower extremities strength, 
and the stand-and-sit from a chair test) and obtained a blood sample. The diagnosis of the frailty 
syndrome was based on the Fried criteria (weakness, low speed, low physical activity, exhaustion, 
and weight loss). For this analysis, participants from the second wave of data collection 2013 – 2015 
were included. 
Genotyping was performing using Illumina Infinium Global Screening Array. The call rate was 0.98, 
3.4% of the sample presented a call rate lower than 95% and were excluded from the analysis. 
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Imputation Panel: HRC (Version r1.1 2016) using Michigan Imputation Server. GWAS was performed 
using SNPTEST logistic regression adjusted for age, sex, and 6 EVs. 
 
UK Biobank (UKB) 
Between 2006 and 2010, 503,325 volunteers (aged 40 to 70 years old) were recruited from across 
the United Kingdom to the UK Biobank study. Genetic data was available on 488,377 UK Biobank 
participants after genotype calling and quality control performed centrally by the UK Biobank team 
(29). We selected 451,447 participants identified as ‘white European’ through self-report and 
verified through principal components analysis based on genotypes. Briefly, principal components 
were generated in the 1000 Genomes Cohort using high-confidence SNPs to obtain their individual 
loadings. These loadings were then used to project all of the UK Biobank samples into the same 
principal component space and individuals were then clustered using principal components 1 to 4 
(see (30) for details). Imputation of 39,235,157 genetic variants from the Haplotype Reference 
Consortium panel was performed using IMPUTE4 centrally by the UK Biobank team (29). After 
filtering for variants with MAF ≥0.1%, missingness <1.5%, imputation quality >0.1 and with Hardy-
Weinberg equilibrium (HWE) P>1x10-6 within the European-descent participants 11,516,125 imputed 
autosomal variants were eligible for the analyses. We used BOLT-LMM v2.3.2 to model the 
associations between imputed variants (dosages) and each phenotype (12) using LD Score provided 
with the package for European populations. Although this means we have not used a logistic 
regression model, this approach has the advantage that the linear mixed effects model approach 
robustly accounts for relatedness and population structure.  
 
Wisconsin Longitudinal Study (WLS) 
The Wisconsin Longitudinal Study (WLS) is a one-third sample of all 1957 Wisconsin high school 
graduates and a randomly selected sibling (31). These respondents were originally empaneled with 
an in-person questionnaire at age 18 (1957), which was followed with a mail survey of parents in 
1964, telephone survey in 1975, mail and telephone surveys in 1993 and 2004 and in-person 
interviews in 2011, where data on grip strength was collected from participants. The WLS has a high 
response rate, exceeding 80 percent in most rounds of data collection. Between In 2006-11, the WLS 
collected saliva samples from respondents using Oragene kits (32). After quality control, a total of 
9,012 graduate and sibling respondents were genotyped at ~710,000 markers (before imputation) 
utilizing the Omni-Express beadchip. Genotyping was complete at Johns Hopkins’ Center for 
Inherited Disease Research (CIDR) and data cleaning was performed in collaboration with the 
Genetic Analysis Center at the University of Washington. The detailed procedures employed to 
generate the genetic data are available on the WLS website 
(https://www.ssc.wisc.edu/wlsresearch/documentation/GWAS). Genotype imputation using the 
Haplotype Reference Consortium (HRC) v1.1 panel was performed.  
In the sample aged 60 or over at grip assessment (n=7,190) BOLT-LMM was used to model 
associations between the imputation variants and low grip strength phenotypes. Covariates used 
were age at grip strength measurement, age at DNA collection, 10 principal components, and sex. 
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WLS Data, documentation and other material are accessible at 
http://www.ssc.wisc.edu/wlsresearch/.   
 
 
GWAS meta-analysis methods 
Each cohort used the optimum GWAS method available at the time. Most used logistic regression 
models or equivalent to derive Odds Ratios. Some (HRS, UK Biobank and WLS) were able to use 
BOLT-LMM to maximise discovery power by including all related participants (appropriate 
adjustment made in the Linear Mixed Model methods but larger sample sizes are required for the 
method to be robust). While BOLT-LMM was developed for quantitative traits, it can be used for 
binary traits as long as they are sufficiently balanced (cases >10% of sample) (33). We therefore 
converted the regression coefficients from BOLT-LMM to Odds Ratios using a method published by 
Lloyd-Jones in 2018 (34) prior to meta-analysis. This method uses the genetic effect (the beta), allele 
frequency, and sample prevalence to estimate the Odds Ratio from the Beta. We used the published 
R function to perform the transformation from the HRS, UK Biobank and WLS results 
(https://github.com/lukelloydjones/ORShiny/blob/master/shiny_lmor_func.R). Finally, inverse 














Supplementary Figures 2A-O: LocusZoom plots for the 15 EWGSOP low grip loci 
The LocusZoom online tool (http://locuszoom.org) was used to plot the regions around the 15 loci 
(panels A to O) significantly (p<5*10-8) associated with low grip strength in this GWAS meta-analysis. 












Supplementary Figure 2B: rs143384 (chr20:34025756) 
 
 





Supplementary Figure 2D: rs3118903 (chr13:51099577) 
 
 





Supplementary Figure 2F: rs11236213 (chr11:74394369) 
 
 





Supplementary Figure 2H: rs143459567 (chr16:24600412) 
 
 





Supplementary Figure 2J: rs958685 (chr2:70703847) 
 
 




Supplementary Figure 2L: rs79723785 (chr19:55818225) 
 
 





Supplementary Figure 2N: rs8061064 (chr16:53912364) 
 
 





Supplementary Figure 3: Plot of Mendelian randomisation analysis of depression SNPs on 
low grip strength (EWGSOP) in females only 
 
Scatter plot of estimated SNP effects on low grip strength (Dynapenia) European Working Group on 
Sarcopenia definition against estimated SNP effects on Depression; GWAS meta-analysis N = 132,443 
female participants (biologically independent samples) with n=33,548 cases of EWGSOP defined low 





Supplementary Table 1: Summary of cohorts included in the meta-analysis 
Study 
Number of 













>= 60 meeting 




Males aged >= 
60 meeting 











ARIC 650 289 217 134 2,025 1,630 3,655 
BASE-II 55 19 5 4 779 752 1,531 
BPROOF 328 145 137 64 1,244 1,275 2,519 
CHS 601 201 231 88 1,855 1,206 3,061 
EPIC-Norfolk 926 503 326 219 3,962 3,546 7,508 
FHS 400 142 153 60 1,461 1,245 2,706 
HRS 2,380 1,244 1,089 665 6,164 4,650 10,814 
InCHIANTI 162 75 90 48 458 361 819 
LASA I 121 77 43 37 249 255 504 
LASA II 192 85 68 36 632 589 1,221 
Long Life Family Study 824 586 446 397 1,788 1,571 3,359 
MrOS Gothenburg 0 35 0 10 0 941 941 
MrOS Malmo 0 29 0 12 0 891 891 
ROSMAP 1 661 198 346 129 1,096 473 1,569 
ROSMAP 2 197 48 108 32 266 95 361 
Rotterdam Study I 511 234 253 121 853 587 1,440 
Rotterdam Study II 273 137 121 58 684 565 1,249 
Rotterdam Study III 146 86 41 36 844 640 1,484 
SHIP 96 35 43 8 523 513 1,036 
TSHA 844 447 525 316 1,218 882 2,100 
UK Biobank 24,229 8,807 8,966 3,941 105,597 94,968 200,565 
WLS 993 585 393 319 3,770 3,420 7,190 
Total 34,589 14,007 13,601 6,734 135,468 121,055 256,523 
 EWGSOP total= 48,596 FNIH total= 20,335    
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Supplementary Table 2: Genomic risk loci associated with low grip strength EWGSOP definition, Female only 
 
   EWGSOP Female EWGSOP All EWGSOP Male  
RSID Chr Position P-value EA  OA EAF Effect P-value Effect P-value Effect Nearest gene* 
rs34415150 6 32560477 1.2E-16 G A 0.18 0.1001 4.42E-17 0.0833 1.02E-03 0.0582 HLA-DRB1 
rs143384 20 34025756 5.87E-13 A G 0.59 0.0657 4.47E-13 0.0545 2.45E-03 0.0401 GDF5 
rs201754 13 51078446 4.43E-10 C T 0.22 0.0668 3.30E-10 0.0554 3.97E-02 0.0321 DLEU1 
rs4764133 12 15064363 3.9E-09 T C 0.38 0.054 1.92E-09 0.0454 2.42E-02 0.03 ERP27 
rs2899611 15 58327347 1.03E-08 G T 0.51 0.0515 6.01E-09 0.0431 5.33E-03 0.0363 ALDH1A2 
rs11236213 11 74394369 2.72E-08 G A 0.69 0.054 3.01E-10 0.0504 3.13E-04 0.0508 RN7SKP297 
rs7185040 16 2145787 3.36E-08 C A 0.18 0.0642 5.57E-08 0.052 3.91E-02 0.0348 PKD1 
rs550258 18 46860643 4.81E-08 T C 0.35 0.0511 8.51E-10 0.0473 2.23E-03 0.0414 DYM 
 
EA = Effect allele = dynapenia likelihood-increasing allele (flipped if necessary for all related columns) 
OA = Other allele 
EAF = Effect allele frequency 
Effect = beta for association with dynapenia from METAL meta-analysis 






Supplementary Table 3: Genomic risk loci associated with low grip strength EWGSOP definition, Male only 
 
   EWGSOP Male EWGSOP All EWGSOP Female  
RSID Chr Position P-value EA  OA EAF Effect P-value Effect P-value Effect Nearest gene* 
rs774787160 21 41996684 1.39E-08 A ACACATCCAAAAG 0.73 0.0983 2.99E-03 0.0275 9.27E-01 -0.001 DSCAM 
rs145933237 3 31188133 2.05E-08 C G 0.02 0.2688 2.04E-06 0.1344 1.06E-02 0.0898 hsa-mir-466 
rs35225200 4 1.03E+08 2.91E-08 C A 0.08 0.1289 1.67E-10 0.0859 8.46E-05 0.0647 SLC39A8 
 
EA = Effect allele = dynapenia likelihood-increasing allele (flipped if necessary for all related columns) 
OA = Other allele 
EAF = Effect allele frequency 
Effect = beta for association with dynapenia from METAL meta-analysis 




Supplementary Table 4: Genomic risk loci associated with low grip strength FNIH definition 
 
RSID Chr Position EA  OA EAF Effect P-value Nearest gene* 
GTEx gene expression 
increased ‡ GTEx gene expression decreased 





rs3771501 2 70717653 A G 0.47 0.0697 5.04E-11 TGFA TGFA (Ts)† TGFA (Bcor, Bcau, Bhyp, Bacc)† 
rs1403785912* 9 4284961 AT A 0.52 0.0765 4.32E-09 GLIS3 RP11-358M14.2*  
rs12456780 18 46947541 T A 0.33 0.0633 1.29E-08 DYM  DYM 
rs191252760 4 61454905 G A 0.02 0.1863 3.17E-08 AC095061.1  ADGRL3 
 
† GTEx v8 differential expression by tissue – Ts = Testis; Bcor = Brain – Cortex; Bcau = Brain - Caudate (basal ganglia); Bhyp = Brain – Hypothalamus; Bacc = 
Brain – Anterior cingulate cortex; Asub = Adipose – subcutaneous; Wb = Whole blood; Esom = Esophagus – mucosa; Skse = Skin sun exposed lower leg; Snse 
= Skin non-sun exposed lower leg; Thy = Thyroid; Adips = Adipose – Subcutaneous; Adipv = Adipose - Visceral (Omentum); Esog = Esophagus - 
Gastroesophageal Junction; Haa = Heart - Atrial Appendage; Hlv = Heart - Left Ventricle; Liv = Liver.         
* SNP not found in GTEx v8 - rs3934283 used as proxy (r2=0.995, FNIH low grip p-value=3.02*10-6) 
EA = Effect allele = dynapenia likelihood-increasing allele (flipped if necessary for all related columns) 
OA = Other allele 
EAF = Effect allele frequency 
Effect = beta for association with dynapenia from METAL meta-analysis 




Supplementary Table 5: Genetic correlations with low grip strength (EWGSOP) 
 
Phenotype rg se p h2_obs h2_obs_se h2_int h2_int_se gcov_int gcov_int_se Reference 
Osteoarthritis 0.2972 0.0626 2.0E-06 0.0635 0.0085 1.0099 0.0064 0.0413 0.0048 Zengini 2018 (PMID: 29559693) 
Coronary Artery Disease 0.1948 0.0301 9.1E-11 0.057 0.0031 0.9934 0.015 0.0158 0.0059 van der Haarst 2018 (PMID: 29212778) 
Type-2 Diabetes 0.1582 0.0307 2.7E-07 0.1952 0.0095 1.0782 0.0232 1.80E-02 0.0067 Mahajan 2018 (PMID: 30297969) 
Alzheimer's Disease 0.157 0.0787 4.6E-02 0.0079 0.0047 1.0526 0.058 0.0093 0.0048 Jansen 2019 (PMID 30617256) 
Rheumatoid Arthritis 0.1267 0.0413 2.1E-03 0.1473 0.0247 0.943 0.0114 0.0053 0.0044 Okada 2014 (PMID:  24390342) 
Ischemic Stroke 0.1078 0.0546 4.8E-02 0.0128 0.0014 1.0349 0.0073 0.0093 0.0053 Malik 2018 (PMID: 29531354) 
Breast Cancer 0.0453 0.0315 1.5E-01 0.1358 0.0114 1.0917 0.02 0.0114 0.0059 Michailidou 2017 (PMID: 29059683) 
Osteoporotic Fracture Risk 0.0164 0.0514 7.5E-01 0.0216 0.0024 0.9877 0.0065 0.0109 0.0047 Trajanoska 2018 (PMID: 30158200) 
Chronic Kidney Disease 0.0042 0.0491 9.3E-01 0.167 0.0661 0.9522 0.014 0.0044 0.0049 Pattaro 2016 (PMID: 26831199) 
Prostate Cancer 0.0037 0.0484 9.4E-01 0.0575 0.0069 1.071 0.0226 0.0049 0.0053 Schumacher 2018 (PMID: 29892016) 
Waist:hip Ratio (adj. BMI) 0.1298 0.0274 2.3E-06 0.1162 0.0056 1.1379 0.0267 0.0384 0.0071 Pulit 2019 (PMID: 30239722) 
Body Mass Index 0.0908 0.0249 2.7E-04 0.2091 0.0064 1.031 0.0257 0.0075 0.0081 Yengo 2018 (PMID: 30124842) 
Appendicular lean muscle mass -0.265 0.0582 5.3E-06 0.1804 0.0205 0.995 0.0073 -0.0111 0.0057 Zillikens 2017 (PMID: 28724990) 
Whole-body lean muscle mass -0.3089 0.0607 3.6E-07 0.131 0.0152 0.9993 0.0077 -0.0106 0.006 Zillikens 2017 (PMID: 28724990) 
Height -0.3739 0.0232 2.1E-58 0.4337 0.017 1.6406 0.0918 -0.1278 0.0148 Yengo 2018 (PMID: 30124842) 
Grip strength -0.952 0.0167 0.0E+00 0.1355 0.0047 1.0718 0.017 -0.4084 0.0095 Analysis in UK Biobank Europeans 
 
LD Score Regression methods using published GWAS summary statistics (https://github.com/bulik/ldsc) 
Phenotype = GWAS for genetic correlation with dynapenia 
rg = genetic correlation, se = standard error of rg, p = p-value for rg 
h2_obs, h2_obs_se = observed scale h2 for trait 2 and standard error 
h2_int, h2_int_se = single-trait LD Score regression intercept for trait 2 and standard error 
gcov_int, gcov_int_se = cross-trait LD Score regression intercept and standard error. 
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Supplementary Table 6: ICD-10 and UK Biobank self-reported codes used in sensitivity analysis 
 
Condition UK Biobank self-reported fields ICD-10 codes OPCS codes N 
Osteoarthritis 1465 M15.0; M15.1; M15.2; M15.9; 
M16.0; M16.1; M17.0; M17.1; 
M18.0; M18.1; M19.0 
O18*; W40*; W41*; W42*; 
W37*; W38*; W39*; W46*; 
W47*; W48*; W93*; W94*; 
W95* 
29,380 
Rheumatoid arthritis 1464 M05; M06   3,263 
Rhizarthrosis    M18; M180; M181; M182; 
M183; M184; M185; M189 
  355 
Osteoporosis 1309 M80; M81   6,308 
Dupuytren's contracture  1544 M720; M7204 T521; T522; T525; T526; T541; 
T561; T562 
1,455 
Any autoimmune condition 1234; 1522; 1428; 1464; 1381; 
1313; 1382; 1261; 1456; 1463; 
1477; 1453; 11222 
D69*; D758; D141; D862; E271; 
E05; E051; E063; E100; E101; 
E102; E103; E104; E105; E106; 
E107; E108; E109; G35; G737; 
G70*; H30*; K900; K510; K512; 
K513; K514; K515; K518; K519; 
L40; L400; L401; L402; L403; 
L404; L405; L408; L409; L12*; 
L10*; L511; M023; M0230; 
M0236; M0239; M028; M0281; 
M0284; M0285; M0286; 
M0287; M029; M0290; M0293; 
M0294; M0295; M0296; 
M0297; M0299; M06*; M320; 
M321; M328; M329; M45; 
M350; M30*; M34*; M352 
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